Idexx Laboratories

Health Care Health Care Equipment Westbrook, Maine Last filing Feb 20, 2026 · FY2025

                    Revenue
                    FY2025
                
$4.3B
                    3y CAGR +8.5%
                    
                    P68
                    
                    n/a
                    
                    Net income
                    FY2025
                
$1.1B
                    Net margin +24.6%
                    
                    P83
                    
                    n/a
                    
                    Total assets
                    FY2025
                
$3.4B
                    ROA +31.6%
                    
                    P100
                    
                    n/a
                    
                    Operating cash flow
                    FY2025
                
$1.2B
                    FCF margin +24.6%
                    
                    P90
                    
                    n/a

19 yrs · FY2006–FY2025 1 gap (2007) 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s revenue.

Balance Sheet

Assets, liabilities, and equity

34 accounts · 1 year

Total assets $3.4B

Total liabilities $1.7B

Shareholders equity $1.6B

Account	2025	Trend
Assets
Cash and Cash Equivalents	4.2%
Accounts Receivable	12.8%
Inventory	8.8%
Prepaid Expenses	1.3%
Other Current Assets	7.1%
Total Current Assets	32.9%
Property,Plant and Equipment	17.4%
Operating Lease Assets	2.9%
Goodwill	9.6%
Intangible Assets	2.6%
Deferred Tax Assets	0.6%
Other Noncurrent Assets	12.6%
Total Assets	77.9%
Liabilities
Accounts Payable	2.6%
Accrued Liabilities	12.3%
Deferred Revenue	0.8%
Current Portion of Long Term Debt	1.7%
Operating Lease Liabilities	0.6%
Other Current Liabilities	1.3%
Total Current Liabilities	26.7%
Long Term Debt	8.7%
Deferred Revenue Noncurrent	0.7%
Operating Lease Liabilities Noncurrent	2.4%
Deferred Tax Liabilities	0.7%
Other Noncurrent Liabilities	1.3%
Total Liabilities	40.6%
Equity
Preferred Stock	0.0%
Common Stock	0.3%
Additional Paid In Capital	42.4%
Retained Earnings	148.5%
Treasury Stock	152.5%
Accumulated Other Comprehensive Income	-1.6%
Total Stockholders Equity	37.3%
Total Liabilitiesand Equity	77.9%

Income Statement

Revenue, expense, and profitability

18 accounts · 1 year

Revenue $4.3B

Operating income $1.4B

Net income $1.1B

Account	2025	Trend
IncomeStatement
Revenues Total Revenue	100.0%
Expenses Cost of Revenue	38.2%
Expenses Research and Development	5.8%
Expenses Selling,General and Administrative	9.4%
Expenses Depreciation and Amortization	3.4%
Expenses Share Based Compensation	1.4%
Expenses Operating Expenses	30.2%
Other Income Expense Gross Profit	61.8%
Other Income Expense Operating Income	31.6%
Other Income Expense Interest Expense	0.9%
Other Income Expense Income Before Tax	30.8%
Income Tax Income Tax Expense	6.2%
net Income net Income	24.6%
net Income Comprehensive Income	25.2%
Earnings Per Share Basic Eps	0.0%
Earnings Per Share Diluted Eps	0.0%
Earnings Per Share Weighted Average Shares Basic	1.9%
Earnings Per Share Weighted Average Shares Diluted	1.9%

Cash Flow Statement

Operating, investing, and financing flows

20 accounts · 1 year

Operating cash flow $1.2B

Investing cash flow $-136.2M

Financing cash flow $-1.2B

Account	2025	Trend
CashFlow
Operating Activities net Income	24.6%
Operating Activities Depreciation and Amortization	0.5%
Operating Activities Stock Based Compensation	1.4%
Operating Activities Deferred Income Taxes	3.0%
Operating Activities Changes In Operating Assets and Liabilities	1.6%
Operating Activities Other Non Cash Items	0.1%
Operating Activities net Cash From Operating Activities	27.5%
Investing Activities Capital Expenditures	2.9%
Investing Activities Business Acquisitions	0.0%
Investing Activities Other Investing Activities	0.1%
Investing Activities net Cash From Investing Activities	-3.2%
Financing Activities Repayment of Debt	4.1%
Financing Activities Repurchase of Common Stock	28.3%
Financing Activities Proceeds From Stock Issuance	2.2%
Financing Activities Tax Withholding On Stock Based Compensation	0.2%
Financing Activities net Cash From Financing Activities	-27.1%
Cash Reconciliation Effect of Exchange Rate On Cash	0.3%
Cash Reconciliation net Change In Cash	-2.5%
Cash Reconciliation Cash At Beginning of Period	4.2%
Cash Reconciliation Cash At End of Period	4.2%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 1 year

Ratio	2025
Profitability
Gross margin	+61.8%
Operating margin	+31.6%
Net margin	+24.6%
FCF margin	+24.6%
Growth
Revenue CAGR (3y)	+8.5%
Returns
ROE	+66.0%
ROA	+31.6%
ROIC	+58.0%
Liquidity
Current ratio	1.23x
Quick ratio	0.64x
Leverage
D/E	1.09x
Interest coverage	35.01x
Efficiency
Asset turnover	1.28x
Cash conversion cycle	+106d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Idexx Laboratories

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history